{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T03:04:20Z","timestamp":1776135860839,"version":"3.50.1"},"reference-count":90,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.phrs.2016.03.005","type":"journal-article","created":{"date-parts":[[2016,3,11]],"date-time":"2016-03-11T07:32:37Z","timestamp":1457681557000},"page":"85-92","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"special_numbering":"C","title":["Cannabidiol and epilepsy: Rationale and therapeutic potential"],"prefix":"10.1016","volume":"107","author":[{"given":"Antonio","family":"Leo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilio","family":"Russo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Elia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2016.03.005_bib0005","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nrn3482","article-title":"Mechanisms of epileptogenesis: a convergence on neural circuit dysfunction","volume":"14","author":"Goldberg","year":"2013","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.phrs.2016.03.005_bib0010","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S1474-4422(10)70310-0","article-title":"Mechanisms of epileptogenesis and potential treatment targets","volume":"10","author":"Pitkanen","year":"2011","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.phrs.2016.03.005_bib0015","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s13311-013-0250-1","article-title":"Searching for the ideal antiepileptogenic agent in experimental models: single treatment versus combinatorial treatment strategies","volume":"11","author":"White","year":"2014","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.phrs.2016.03.005_bib0020","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1111\/bph.13121","article-title":"Antidepressants but not antipsychotics have antiepileptogenic effects with limited effects on comorbid depressive-like behaviour in the wag\/rij rat model of absence epilepsy","volume":"172","author":"Citraro","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.phrs.2016.03.005_bib0025","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s13311-014-0257-2","article-title":"Past and present definitions of epileptogenesis and its biomarkers","volume":"11","author":"Pitkanen","year":"2014","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.phrs.2016.03.005_bib0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brainresbull.2015.02.004","article-title":"Antiepileptogenic effects of the selective cox-2 inhibitor etoricoxib, on the development of spontaneous absence seizures in wag\/rij rats","volume":"113","author":"Citraro","year":"2015","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.phrs.2016.03.005_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2016.03.039","article-title":"Mtor activity as a new therapeutic strategy in epilepsy","author":"Citraro","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2016.03.005_bib0040","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1586\/14737175.6.3.397","article-title":"Refractory epilepsy: mechanisms and solutions","volume":"6","author":"Kwan","year":"2006","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.phrs.2016.03.005_bib0045","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/S1474-4422(12)70153-9","article-title":"Adverse effects of antiepileptic drugs","volume":"11","author":"Perucca","year":"2012","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.phrs.2016.03.005_bib0050","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1111\/j.1528-1167.2012.03488.x","article-title":"Depressive and anxiety disorders in epilepsy: do they differ in their potential to worsen common antiepileptic drug-related adverse events?","volume":"53","author":"Kanner","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.phrs.2016.03.005_bib0055","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1111\/bph.13121","article-title":"Antidepressants but not antipsychotics have antiepileptogenic effects with limited effects on comorbid depressive-like behavior in the wag\/rij rat model of absence epilepsy","volume":"172","author":"Citraro","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.phrs.2016.03.005_bib0060","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1007\/s13311-014-0318-6","article-title":"Comparative analysis of the treatment of chronic antipsychotic drugs on epileptic susceptibility in genetically epilepsy-prone rats","volume":"12","author":"Citraro","year":"2015","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.phrs.2016.03.005_bib0065","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1056\/NEJMra1407304","article-title":"Cannabinoids in the treatment of epilepsy","volume":"373","author":"Friedman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2016.03.005_bib0070","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s13311-015-0375-5","article-title":"Cannabinoids and epilepsy","volume":"12","author":"Rosenberg","year":"2015","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.phrs.2016.03.005_bib0075","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/epi.12631","article-title":"Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders","volume":"55","author":"Devinsky","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.phrs.2016.03.005_bib0080","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/978-3-319-20825-1_10","article-title":"Cannabis and endocannabinoid signaling in epilepsy","volume":"231","author":"Katona","year":"2015","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.phrs.2016.03.005_bib0085","doi-asserted-by":"crossref","DOI":"10.1016\/S1474-4422(16)00002-8","article-title":"Cannabidiol for epilepsy: trying to see through the haze","author":"Detyniecki","year":"2016","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.phrs.2016.03.005_bib0090","first-page":"CD009270","article-title":"Cannabinoids for epilepsy","volume":"3","author":"Gloss","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.phrs.2016.03.005_bib0095","first-page":"1","article-title":"Cannabidiol as potential treatment in refractory pediatric epilepsy","author":"Paolino","year":"2015","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.phrs.2016.03.005_bib0100","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1056\/NEJMc1512758","article-title":"Cannabinoids in the treatment of epilepsy","volume":"374","author":"Killestein","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2016.03.005_bib0105","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.yebeh.2014.08.135","article-title":"Cannabis, cannabidiol, and epilepsy\u2ffffrom receptors to clinical response","volume":"41","author":"Szaflarski","year":"2014","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.phrs.2016.03.005_bib0110","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/epi.13060","article-title":"Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy","volume":"56","author":"Geffrey","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.phrs.2016.03.005_bib0115","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s13311-015-0377-3","article-title":"Molecular targets of cannabidiol in neurological disorders","volume":"12","author":"Ibeas Bih","year":"2015","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.phrs.2016.03.005_bib0120","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/sj.bjp.0707133","article-title":"Cannabidiol displays unexpectedly high potency as an antagonist of cb1 and cb2 receptor agonists in vitro","volume":"150","author":"Thomas","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.phrs.2016.03.005_bib0125","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/bph.12944","article-title":"Are cannabidiol and delta(9)\u2ffftetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review","volume":"172","author":"McPartland","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.phrs.2016.03.005_bib0130","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/sj.bjp.0707442","article-title":"The diverse cb1 and cb2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin","volume":"153","author":"Pertwee","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.phrs.2016.03.005_bib0135","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s11064-005-6978-1","article-title":"Agonistic properties of cannabidiol at 5-ht1a receptors","volume":"30","author":"Russo","year":"2005","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.phrs.2016.03.005_bib0140","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.neuropharm.2013.03.027","article-title":"Mechanisms of cannabidiol neuroprotection in hypoxic-ischemic newborn pigs: role of 5ht(1a) and cb2 receptors","volume":"71","author":"Pazos","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.phrs.2016.03.005_bib0145","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1111\/j.1476-5381.2010.01166.x","article-title":"Effects of cannabinoids and cannabinoid-enriched cannabis extracts on trp channels and endocannabinoid metabolic enzymes","volume":"163","author":"De Petrocellis","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.phrs.2016.03.005_bib0150","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1021\/cn5000524","article-title":"Nonpsychotropic plant cannabinoids, cannabidivarin (cbdv) and cannabidiol (cbd), activate and desensitize transient receptor potential vanilloid 1 (trpv1) channels in vitro: potential for the treatment of neuronal hyperexcitability","volume":"5","author":"Iannotti","year":"2014","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.phrs.2016.03.005_bib0155","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejphar.2011.01.013","article-title":"Cannabinoids inhibit the synaptic uptake of adenosine and dopamine in the rat and mouse striatum","volume":"655","author":"Pandolfo","year":"2011","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.phrs.2016.03.005_bib0160","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0022-3565(25)30230-2","article-title":"Cannabinoids: influence on neurotransmitter uptake in rat brain synaptosomes","volume":"194","author":"Banerjee","year":"1975","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.phrs.2016.03.005_bib0165","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1084\/jem.20120242","article-title":"Cannabinoids suppress inflammatory and neuropathic pain by targeting alpha3 glycine receptors","volume":"209","author":"Xiong","year":"2012","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.phrs.2016.03.005_bib0170","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1159\/000201556","article-title":"The nonpsychotropic cannabinoid cannabidiol modulates and directly activates alpha-1 and alpha-1-beta glycine receptor function","volume":"83","author":"Ahrens","year":"2009","journal-title":"Pharmacology"},{"key":"10.1016\/j.phrs.2016.03.005_bib0175","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/jcpt.12235","article-title":"Phytocannabinoids and epilepsy","volume":"40","author":"dos Santos","year":"2015","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.phrs.2016.03.005_bib0180","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.seizure.2012.03.001","article-title":"Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures","volume":"21","author":"Jones","year":"2012","journal-title":"Seizure"},{"key":"10.1016\/j.phrs.2016.03.005_bib0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2016.01.033","article-title":"Cannabidiol, neuroprotection and neuropsychiatric disorders","author":"Campos","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2016.03.005_bib0190","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.3233\/JAD-140921","article-title":"Long-term cannabidiol treatment prevents the development of social recognition memory deficits in alzheimer\u2fffs disease transgenic mice","volume":"42","author":"Cheng","year":"2014","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.phrs.2016.03.005_bib0195","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s13311-015-0387-1","article-title":"Cannabidiol as a potential treatment for anxiety disorders","volume":"12","author":"Blessing","year":"2015","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.phrs.2016.03.005_bib0200","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.pharmthera.2012.12.002","article-title":"Endocannabinoid system and mood disorders: priming a target for new therapies","volume":"138","author":"Micale","year":"2013","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2016.03.005_bib0205","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1007\/s13311-015-0382-6","article-title":"Cannabinoids and schizophrenia: risks and therapeutic potential","volume":"12","author":"Manseau","year":"2015","journal-title":"Neurotherapeutics"},{"issue":"Suppl. 4","key":"10.1016\/j.phrs.2016.03.005_bib0210","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/epi.12298","article-title":"Issues related to symptomatic and disease-modifying treatments affecting cognitive and neuropsychiatric comorbidities of epilepsy","volume":"54","author":"Brooks-Kayal","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.phrs.2016.03.005_bib0215","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.neuropharm.2015.12.017","article-title":"Cannabidiol induces rapid-acting antidepressant-like effects and enhances cortical 5-ht\/glutamate neurotransmission: role of 5-ht receptors","volume":"103","author":"Linge","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.phrs.2016.03.005_bib0220","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.pharmthera.2011.09.002","article-title":"Phytocannabinoids as novel therapeutic agents in cns disorders","volume":"133","author":"Hill","year":"2012","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2016.03.005_bib0225","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.eplepsyres.2015.01.001","article-title":"Progress report on new antiepileptic drugs: a summary of the twelfth eilat conference (eilat xii)","volume":"111","author":"Bialer","year":"2015","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.phrs.2016.03.005_bib0230","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/bph.12321","article-title":"Cannabidivarin-rich cannabis extracts are anticonvulsant in mouse and rat via a cb1 receptor-independent mechanism","volume":"170","author":"Hill","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.phrs.2016.03.005_bib0235","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/ptr.2625","article-title":"Cannabidiol in medicine: a review of its therapeutic potential in cns disorders","volume":"23","author":"Scuderi","year":"2009","journal-title":"Phytother. Res."},{"key":"10.1016\/j.phrs.2016.03.005_bib0240","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/0014-2999(82)90264-3","article-title":"Effects of cannabidiol on behavioral seizures caused by convulsant drugs or current in mice","volume":"83","author":"Consroe","year":"1982","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.phrs.2016.03.005_bib0245","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/0091-3057(82)90418-X","article-title":"Effects of marihuana cannabinoids on seizure activity in cobalt-epileptic rats","volume":"16","author":"Colasanti","year":"1982","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.phrs.2016.03.005_bib0250","doi-asserted-by":"crossref","first-page":"437S","DOI":"10.1002\/j.1552-4604.1981.tb02624.x","article-title":"The cannabinoids as potential antiepileptics","volume":"21","author":"Karler","year":"1981","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2016.03.005_bib0255","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/j.2042-7158.1973.tb10660.x","article-title":"Letter: cannabidiol and Cannabis sativa extract protect mice and rats against convulsive agents","volume":"25","author":"Carlini","year":"1973","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.phrs.2016.03.005_bib0260","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S0022-3565(25)30824-4","article-title":"Cannabidiol\u2fffantiepileptic drug comparisons and interactions in experimentally induced seizures in rats","volume":"201","author":"Consroe","year":"1977","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.phrs.2016.03.005_bib0265","doi-asserted-by":"crossref","first-page":"206","DOI":"10.2174\/1389200217666151210142051","article-title":"Cannabinoids and cytochrome p450 interactions","volume":"17","author":"Zendulka","year":"2016","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.phrs.2016.03.005_bib0270","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1124\/jpet.109.159145","article-title":"Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo","volume":"332","author":"Jones","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.phrs.2016.03.005_bib0275","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.yebeh.2013.03.009","article-title":"The role of potassium bk channels in anticonvulsant effect of cannabidiol in pentylenetetrazole and maximal electroshock models of seizure in mice","volume":"28","author":"Shirazi-zand","year":"2013","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.phrs.2016.03.005_bib0280","first-page":"1","article-title":"Are big potassium-type ca-activated potassium channels a viable target for the treatment of epilepsy?","author":"Leo","year":"2015","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.phrs.2016.03.005_bib0285","doi-asserted-by":"crossref","first-page":"3","DOI":"10.5698\/1535-7511-14.s2.3","article-title":"Epilepsy and inflammation in the brain: overview and pathophysiology","volume":"14","author":"Vezzani","year":"2014","journal-title":"Epilepsy Curr."},{"key":"10.1016\/j.phrs.2016.03.005_bib0290","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.tins.2012.11.008","article-title":"Glia and epilepsy: excitability and inflammation","volume":"36","author":"Devinsky","year":"2013","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.phrs.2016.03.005_bib0295","first-page":"8820","article-title":"High dosage of cannabidiol (cbd) alleviates pentylenetetrazole-induced epilepsy in rats by exerting an anticonvulsive effect","volume":"8","author":"Mao","year":"2015","journal-title":"Int. J. Clin. Exp. Med."},{"key":"10.1016\/j.phrs.2016.03.005_bib0300","doi-asserted-by":"crossref","DOI":"10.1007\/s12031-015-0703-6","article-title":"Cannabidiol post-treatment alleviates rat epileptic-related behaviors and activates hippocampal cell autophagy pathway along with antioxidant defense in chronic phase of pilocarpine-induced seizure","author":"Hosseinzadeh","year":"2016","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.phrs.2016.03.005_bib0305","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1203\/PDR.0b013e318186e5dd","article-title":"Neuroprotective effects of the nonpsychoactive cannabinoid cannabidiol in hypoxic-ischemic newborn piglets","volume":"64","author":"Alvarez","year":"2008","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.phrs.2016.03.005_bib0310","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.2174\/138161208785740054","article-title":"Role of cannabinoids and endocannabinoids in cerebral ischemia","volume":"14","author":"Hillard","year":"2008","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.phrs.2016.03.005_bib0315","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1111\/j.1476-5381.2012.02207.x","article-title":"Cannabidivarin is anticonvulsant in mouse and rat","volume":"167","author":"Hill","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.phrs.2016.03.005_bib0320","doi-asserted-by":"crossref","first-page":"e214","DOI":"10.7717\/peerj.214","article-title":"Cannabidivarin (cbdv) suppresses pentylenetetrazole (ptz)-induced increases in epilepsy-related gene expression","volume":"1","author":"Amada","year":"2013","journal-title":"PeerJ"},{"key":"10.1016\/j.phrs.2016.03.005_bib0325","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1124\/jpet.115.230151","article-title":"The pharmacological basis of cannabis therapy for epilepsy","volume":"357","author":"Reddy","year":"2016","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.phrs.2016.03.005_bib0330","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3109\/03602532.2015.1029635","article-title":"Synthetic cannabinoids pharmacokinetics and detection methods in biological matrices","volume":"47","author":"Castaneto","year":"2015","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.phrs.2016.03.005_bib0335","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/3-540-26573-2_23","article-title":"Pharmacokinetics and metabolism of the plant cannabinoids, delta9-tetrahydrocannabinol, cannabidiol and cannabinol","author":"Huestis","year":"2005","journal-title":"Handb. Exp. Pharmacol."},{"issue":"Suppl. A","key":"10.1016\/j.phrs.2016.03.005_bib0340","doi-asserted-by":"crossref","first-page":"15A","DOI":"10.1155\/2005\/242516","article-title":"Pharmacokinetics of cannabinoids","volume":"10","author":"McGilveray","year":"2005","journal-title":"Pain Res. Manag."},{"key":"10.1016\/j.phrs.2016.03.005_bib0345","doi-asserted-by":"crossref","first-page":"206","DOI":"10.2174\/1389200217666151210142051","article-title":"Cannabinoids and cytochrome p450 interactions","volume":"17","author":"Zendulka","year":"2016","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.phrs.2016.03.005_bib0350","first-page":"167","article-title":"Anti-epileptic action of marijuana- active substances","volume":"8","author":"Ramsey","year":"1949","journal-title":"Fed. Proc."},{"key":"10.1016\/j.phrs.2016.03.005_bib0355","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1001\/jama.1975.03260160054015","article-title":"Anticonvulsant nature of marihuana smoking","volume":"234","author":"Consroe","year":"1975","journal-title":"JAMA"},{"key":"10.1016\/j.phrs.2016.03.005_bib0360","first-page":"439","article-title":"Complex partial seizure symptoms affected by marijuana abuse","volume":"51","author":"Ellison","year":"1990","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.phrs.2016.03.005_bib0365","first-page":"474","article-title":"Grand mal convulsions subsequent to marijuana use. Case report","volume":"28","author":"Keeler","year":"1967","journal-title":"Dis. Nerv. Syst."},{"key":"10.1016\/j.phrs.2016.03.005_bib0370","first-page":"40","article-title":"On the application of cannabis in paediatrics and epileptology","volume":"25","author":"Lorenz","year":"2004","journal-title":"Neuro Endocrinol. Lett."},{"key":"10.1016\/j.phrs.2016.03.005_bib0375","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.yebeh.2012.09.024","article-title":"Seizure exacerbation in two patients with focal epilepsy following marijuana cessation","volume":"25","author":"Hegde","year":"2012","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.phrs.2016.03.005_bib0380","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.pediatrneurol.2015.02.008","article-title":"Pure cannabidiol in the treatment of malignant migrating partial seizures in infancy: a case report","volume":"52","author":"Saade","year":"2015","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.phrs.2016.03.005_bib0385","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1212\/01.WNL.0000127623.03766.75","article-title":"Marijuana use and epilepsy: prevalence in patients of a tertiary care epilepsy center","volume":"62","author":"Gross","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.phrs.2016.03.005_bib0390","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.yebeh.2013.08.037","article-title":"Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy","volume":"29","author":"Porter","year":"2013","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.phrs.2016.03.005_bib0395","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/ene.12081","article-title":"Cannabis and other illicit drug use in epilepsy patients","volume":"21","author":"Hamerle","year":"2014","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.phrs.2016.03.005_bib0400","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.yebeh.2015.04.009","article-title":"Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: a potential role for infantile spasms and lennox-gastaut syndrome","volume":"47","author":"Hussain","year":"2015","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.phrs.2016.03.005_bib0405","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.yebeh.2015.02.043","article-title":"Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy","volume":"45","author":"Press","year":"2015","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.phrs.2016.03.005_bib0410","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/epi.12843","article-title":"Fewer specialists support using medical marijuana and cbd in treating epilepsy patients compared with other medical professionals and patients: result of epilepsia\u2fffs survey","volume":"56","author":"Mathern","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.phrs.2016.03.005_bib0415","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.seizure.2016.01.004","article-title":"Cbd-enriched medical cannabis for intractable pediatric epilepsy: the current israeli experience","volume":"35","author":"Tzadok","year":"2016","journal-title":"Seizure"},{"key":"10.1016\/j.phrs.2016.03.005_bib0420","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1159\/000137430","article-title":"Chronic administration of cannabidiol to healthy volunteers and epileptic patients","volume":"21","author":"Cunha","year":"1980","journal-title":"Pharmacology"},{"key":"10.1016\/j.phrs.2016.03.005_bib0425","first-page":"14","article-title":"Anticonvulsant effect of cannabidiol","volume":"69","author":"Ames","year":"1986","journal-title":"S. Afr. Med. J."},{"key":"10.1016\/j.phrs.2016.03.005_bib0430","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/BF00450585","article-title":"Toward drugs derived from cannabis","volume":"65","author":"Mechoulam","year":"1978","journal-title":"Naturwissenschaften"},{"key":"10.1016\/j.phrs.2016.03.005_bib0435","series-title":"International Conference on Cannabis and Cannabinoids","article-title":"Double-blind clinical study of cannabidiol as a secondary anticonvulsant. Marijuana \u2fff90 International Conference on Cannabis and Cannabinoids","author":"Trembly","year":"1990"},{"key":"10.1016\/j.phrs.2016.03.005_bib0440","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1212\/WNL.0000000000000363","article-title":"Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the guideline development subcommittee of the American academy of neurology","volume":"82","author":"Koppel","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.phrs.2016.03.005_bib0445","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.yebeh.2015.07.042","article-title":"Issues and promise in clinical studies of botanicals with anticonvulsant potential","volume":"52","author":"Ekstein","year":"2015","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.phrs.2016.03.005_bib0450","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S1474-4422(15)00379-8","article-title":"Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial","volume":"15","author":"Devinsky","year":"2016","journal-title":"Lancet Neurol."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661816301797?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661816301797?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T18:56:59Z","timestamp":1748804219000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661816301797"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":90,"alternative-id":["S1043661816301797"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2016.03.005","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cannabidiol and epilepsy: Rationale and therapeutic potential","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2016.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}